TOX, a Novel Regulator of Thymocyte Selection

TOX,胸腺细胞选择的新型调节剂

基本信息

  • 批准号:
    7319650
  • 负责人:
  • 金额:
    $ 39.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-12-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The thymus generates a vast excess of cells that fail to complete maturation and die in situ. This is a result of the processes of beta-selection, positive selection, and negative selection that place stringent controls on various stages of T cell development. Both beta-selection and positive selection are cell differentiation events that result in stable changes in gene expression. There is still much to learn about the molecular control of gene expression during these critical developmental transitions. We have recently identified a gene encoding a novel regulator of thymocyte selection we termed TOX (thymocyte selection associated HMG-box protein). As its name implies, TOX is a member of the HMG-box superfamily of nuclear proteins. HMG-box proteins are architectural factors that bind DNA and regulate formation of mutiprotein transcriptional regulatory complexes and/or are involved in regulating chromatin accessibility. TOX also belongs to a small conserved subfamily of HMG-box proteins. Expression of TOX in the thymus is tightly regulated and is associated with both beta-selection and positive selection. Data indicate that expression of TOX in the thymus of transgenic mice is sufficient to initiate both of these differentiation processes. This includes promotion of CD8 T cell lineage commitment at the expense of CD4 lineage commitment. We propose to further investigate the biological functions of this novel nuclear protein. Specific approaches are outlined to; determine the expression of TOX and family members during lymphocyte development, analyze biochemical characteristics of TOX, determine subcellular and intranuclear localization of the protein, identify signaling pathways that regulate its expression, perform a structure/function analysis of various forms of TOX in vitro and in vivo, produce TOX deficient mice, identify other proteins that interact with domains of TOX and identify gene targets for this nuclear protein in the context of positive selection.
描述(由申请人提供):胸腺产生大量未能完全成熟并原位死亡的细胞。这是β选择,阳性选择和负面选择过程的结果,这些过程将严格控制在T细胞发育的各个阶段。 β选择和阳性选择都是细胞分化事件,导致基因表达稳定变化。在这些关键发育过渡期间,关于基因表达的分子控制仍然有很多要学习的知识。 我们最近确定了一个编码我们称为TOX(胸腺细胞选择相关的HMG-box蛋白)的新型胸腺细胞选择调节剂的基因。顾名思义,TOX是核蛋白质蛋白HMG-box超家族的成员。 HMG-box蛋白是结合DNA并调节烟蛋白转录调节复合物和/或参与调节染色质访问性的结构因子。 TOX还属于HMG-box蛋白的一小部分。托克斯在胸腺中的表达受到严格的调节,并与β选择和阳性选择有关。数据表明,托克斯在转基因小鼠的胸腺中的表达足以启动这两个分化过程。这包括以CD4谱系承诺为代价促进CD8 T细胞谱系承诺。我们建议进一步研究这种新型核蛋白的生物学功能。概述了特定的方法; determine the expression of TOX and family members during lymphocyte development, analyze biochemical characteristics of TOX, determine subcellular and intranuclear localization of the protein, identify signaling pathways that regulate its expression, perform a structure/function analysis of various forms of TOX in vitro and in vivo, produce TOX deficient mice, identify other proteins that interact with domains of TOX and identify gene targets for this nuclear protein in the context of positive选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

JONATHAN G KAYE的其他基金

Regulation of Treg activity by controlling FOXP3 expression
通过控制 FOXP3 表达来调节 Treg 活性
  • 批准号:
    9373172
    9373172
  • 财政年份:
    2017
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
A novel small molecule probe to study TOX-family transcriptional regulators
一种用于研究 TOX 家族转录调节因子的新型小分子探针
  • 批准号:
    9324512
    9324512
  • 财政年份:
    2017
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Structure/Function Analysis of TOX, a Key Regulator of NK Cell Development
NK 细胞发育的关键调节因子 TOX 的结构/功能分析
  • 批准号:
    8702947
    8702947
  • 财政年份:
    2014
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Role of Nuclear Factor TOX in Germinal Center Reactions
核因子 TOX 在生发中心反应中的作用
  • 批准号:
    7790233
    7790233
  • 财政年份:
    2008
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Role of Nuclear Factor TOX in Germinal Center Reactions
核因子 TOX 在生发中心反应中的作用
  • 批准号:
    7446924
    7446924
  • 财政年份:
    2008
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Role of Nuclear Factor TOX in Germinal Center Reactions
核因子 TOX 在生发中心反应中的作用
  • 批准号:
    7687579
    7687579
  • 财政年份:
    2008
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
TOX, a Novel Regulator of Thymocyte Selection
TOX,胸腺细胞选择的新型调节剂
  • 批准号:
    6983411
    6983411
  • 财政年份:
    2003
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Role of nuclear factor TOX in lymphocyte development
核因子 TOX 在淋巴细胞发育中的作用
  • 批准号:
    9751160
    9751160
  • 财政年份:
    2003
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
TOX, A Novel Regulator of Thymocyte Selection
TOX,胸腺细胞选择的新型调节剂
  • 批准号:
    8037783
    8037783
  • 财政年份:
    2003
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
TOX, a Novel Regulator of Thymocyte Selection
TOX,胸腺细胞选择的新型调节剂
  • 批准号:
    6828313
    6828313
  • 财政年份:
    2003
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:

相似国自然基金

异源合成棘白菌素B的丝状真菌里氏木霉底盘细胞开发与适配调控
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
异源合成棘白菌素B的丝状真菌里氏木霉底盘细胞开发与适配调控
  • 批准号:
    32200069
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
靶向B23蛋白的稀土金属配合物开发及其在细胞核仁成像中的应用研究
  • 批准号:
    21401158
  • 批准年份:
    2014
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Selective targeting of matrix metalloproteinases for developing preterm labor therapeutics
选择性靶向基质金属蛋白酶用于开发早产疗法
  • 批准号:
    10509786
    10509786
  • 财政年份:
    2023
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
3D Methodology for Interpreting Disease-Associated Genomic Variation in RAG2
解释 RAG2 中疾病相关基因组变异的 3D 方法
  • 批准号:
    10724152
    10724152
  • 财政年份:
    2023
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine
HCV 包膜纳米颗粒疫苗的精密糖工程
  • 批准号:
    10759994
    10759994
  • 财政年份:
    2023
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
DNA sequence selectivity in conventional and aberrant V(D)J recombination
常规和异常 V(D)J 重组中的 DNA 序列选择性
  • 批准号:
    10586433
    10586433
  • 财政年份:
    2023
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别:
Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity
肝脏靶向二氢喹嗪酮 (DHQ) 分子作为乙型肝炎病毒抗病毒药物,毒性降低
  • 批准号:
    10593566
    10593566
  • 财政年份:
    2023
  • 资助金额:
    $ 39.66万
    $ 39.66万
  • 项目类别: